These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23966368)

  • 1. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration.
    Krebs I; Glittenberg C; Ansari-Shahrezaei S; Hagen S; Steiner I; Binder S
    Br J Ophthalmol; 2013 Nov; 97(11):1443-6. PubMed ID: 23966368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S;
    Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ; Koh HJ
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
    You JY; Chung H; Kim HC
    Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
    Tao Y; Jonas JB
    Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
    Fong DS; Custis P; Howes J; Hsu JW
    Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.
    Zweifel SA; Engelbert M; Khan S; Freund KB
    Retina; 2009; 29(10):1527-31. PubMed ID: 19898185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
    Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
    Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration associated with poor initial visual acuity.
    Galbinur T; Averbukh E; Banin E; Hemo I; Chowers I
    Br J Ophthalmol; 2009 Oct; 93(10):1351-2. PubMed ID: 19520693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration.
    Ozdemir H; Karacorlu M; Senturk F; Karacorlu SA; Uysal O
    Acta Ophthalmol; 2012 Feb; 90(1):71-5. PubMed ID: 20163371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.
    Ladas ID; Chatziralli IP; Kotsolis AI; Douvali M; Georgalas I; Theodossiadis PG; Rouvas AA
    Ophthalmologica; 2012; 228(2):93-101. PubMed ID: 22571933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.